CERo Therapeutics Aktie - CERO

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Premium

Current Price

1,42

Gebot

1,36

Fragen

1,42

Volumen

53.508

1,33 Tagesbereich 1,425

1,26 52-Wochen-Bereich 376,00

Handelsende

1,36

Handelsbeginn

1,40

Letzte Trade

1400

1.42

(formt)

Letzter Handelszeitpunkt

Durchschnittliches Volumen (3 Mio.)

29.747.230

Finanzvolumen

US$ 74.168

VWAP

1,3861

CERo Therapeutics Holdings, Inc. Announces Progress in Initiation of Phase 1 Clinical Trial by Executing an Agreement with Contract Research Organization CellCarta to Manage Translational Assays

Company continues toward the initiation of its Phase 1 Clinical Trial in AML for CER-1236 SOUTH SAN FRANSCISCO...

CERo Therapeutics Holdings, Inc. to Present Data at the Society for Immunotherapy of Cancer Spring Scientific March 12-14

New poster to highlight preclinical data of CER-1236 in ovarian cancer SOUTH SAN FRANSCISCO, Calif., March...

CERo Therapeutics Holdings, Inc. Highlights Progress

Increased cash balance and momentum with both Nasdaq and Phase 1 trial initiation mark strong beginning for...

CERo Therapeutics Announces $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

SOUTH SAN FRANSCISCO, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq:...

CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split

SOUTH SAN FRANSCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq:...

CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO

SOUTH SAN FRANCISCO, Calif, Dec. 06, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq:...

CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia

SOUTH SAN FRANCISCO, Calif, Nov. 15, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq:...

CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity

Data presented as part of a poster at the SITC 2024 Conference SOUTH SAN FRANCISCO, Calif., Nov. 11, 2024...

CERo Therapeutics, Inc. Provides Corporate Update

Company announces submission of IND Clinical Hold Complete Response Letter SOUTH SAN FRANCISCO, Calif., Oct...

CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer

SOUTH SAN FRANCISCO, Calif, Oct. 02, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	1.42	1.55	1.26	112334	1.43162085	CS
4	-0.41	-22.4043715847	1.83	2.1	1.26	187716	1.74220079	CS
12	-7.13	-83.3918128655	8.55	10.25	1.26	29747230	5.38320862	CS
26	-7.96	-84.8614072495	9.38	44.77	1.26	49835114	17.08252537	CS
52	-275.58	-99.4873646209	277	376	1.26	26137175	18.89159767	CS
156	-523.58	-99.7295238095	525	1238	1.26	24583054	20.42129839	CS
260	-523.58	-99.7295238095	525	1238	1.26	24583054	20.42129839	CS

CERO - Frequently Asked Questions (FAQ)

What is the current CERo Therapeutics share price?

The current share price of CERo Therapeutics is US$ 1,42

What is the 1 year trading range for CERo Therapeutics share price?

CERo Therapeutics has traded in the range of US$ 1,26 to US$ 376,00 during the past year

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
CRVOCervoMed Inc	US$ 6,15 (160,59%)	158,89M
ZENAZenaTech Inc	US$ 4,5505 (61,94%)	6,89M
OPRXOptimizeRx Corporation	US$ 6,265 (51,33%)	16,41M
SSPEW Scripps Company	US$ 2,05 (43,36%)	18,27M
GRPNGroupon Inc	US$ 13,9807 (43,10%)	11,17M
HITHealth In Tech Inc	US$ 1,32 (-82,31%)	16,73M
SPHLSpringview Holdings Ltd	US$ 1,24 (-79,33%)	10,7M
APDNApplied DNA Sciences Inc	US$ 0,0619 (-57,89%)	35,11M
ZYXIZynex Inc	US$ 3,39 (-51,57%)	3,82M
HEPAHepion Pharmaceuticals Inc	US$ 0,0488 (-41,90%)	79,16M
STISolidion Technology Inc	US$ 0,174899 (38,70%)	584,7M
NVDANVIDIA Corporation	US$ 115,74 (6,42%)	323,86M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	US$ 9,1432 (15,59%)	222,8M
VSTEVast Renewable Ltd	US$ 0,6182 (23,66%)	193,78M
CRVOCervoMed Inc	US$ 6,15 (160,59%)	158,89M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

CERo Therapeutics Holdings Inc (CERO)

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Wichtige Statistiken und Details

CERO Neueste Nachrichten

CERo Therapeutics Holdings, Inc. Announces Progress in Initiation of Phase 1 Clinical Trial by Executing an Agreement with Contract Research Organization CellCarta to Manage Translational Assays

CERo Therapeutics Holdings, Inc. to Present Data at the Society for Immunotherapy of Cancer Spring Scientific March 12-14

CERo Therapeutics Holdings, Inc. Highlights Progress

CERo Therapeutics Announces $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split

CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO

CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia

CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity

CERo Therapeutics, Inc. Provides Corporate Update

CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer

CERo Therapeutics Holdings, Inc. Announces Progress in Initiation of Phase 1 Clinical Trial by Executing an Agreement with Contract Research Organization CellCarta to Manage Translational Assays

CERo Therapeutics Holdings, Inc. to Present Data at the Society for Immunotherapy of Cancer Spring Scientific March 12-14

CERo Therapeutics Holdings, Inc. Highlights Progress

CERo Therapeutics Announces $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split

CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO

CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia

CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity

CERO - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

CERo Therapeutics Holdings Inc (CERO) Börsenkurse

CERo Therapeutics Holdings Inc (CERO)

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Wichtige Statistiken und Details

CERO Neueste Nachrichten

CERo Therapeutics Holdings, Inc. Announces Progress in Initiation of Phase 1 Clinical Trial by Executing an Agreement with Contract Research Organization CellCarta to Manage Translational Assays

CERo Therapeutics Holdings, Inc. to Present Data at the Society for Immunotherapy of Cancer Spring Scientific March 12-14

CERo Therapeutics Holdings, Inc. Highlights Progress

CERo Therapeutics Announces $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split

CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO

CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia

CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity

CERo Therapeutics, Inc. Provides Corporate Update

CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer

CERo Therapeutics Holdings, Inc. Announces Progress in Initiation of Phase 1 Clinical Trial by Executing an Agreement with Contract Research Organization CellCarta to Manage Translational Assays

CERo Therapeutics Holdings, Inc. to Present Data at the Society for Immunotherapy of Cancer Spring Scientific March 12-14

CERo Therapeutics Holdings, Inc. Highlights Progress

CERo Therapeutics Announces $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split

CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO

CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia

CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity

CERO - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen